Do Calming Treats Actually Work for Dogs?

Regulatory context and evidence standards

Calming treats for dogs occupy an unusual regulatory position. In the United States, products marketed as pet supplements are not required to demonstrate clinical efficacy before sale — they are regulated under a framework that prioritizes safety and label accuracy over proof of therapeutic benefit. The distinction between a supplement with demonstrated efficacy and one without is often not apparent from the product label itself.

Hoffman et al. (2021; PMCID: PMC7802882) reviewed the state of veterinary pet supplements and nutraceuticals, finding that while the regulatory framework has improved with the NASC (National Animal Supplement Council) quality seal program, evidence requirements for market entry remain substantially lower than for pharmaceutical drugs. The NASC seal indicates Good Manufacturing Practices compliance and adverse event reporting participation — it does not constitute a clinical efficacy endorsement.

The placebo problem in owner-reported trials

Owner-reported outcomes — the most common measurement modality in canine supplement research — are susceptible to expectation bias. When a study uses the dog owner as the primary assessor of behavioral improvement, the owner's expectation that the treatment is active can produce reported improvements that reflect observer cognition rather than dog behavior.

This problem is documented in the canine supplement literature. Trials using fish-hydrolysate supplements (PMCID: PMC8464231) found measurable behavioral improvements in both active and placebo groups, with owner-reported placebo-group improvements complicating the attribution of active-group changes to the supplement. The study concluded that the behavioral effects observed in the active group could not be cleanly isolated from expectation effects given the within-study placebo response.

More rigorous methodology — blinded assessors, video behavioral coding, objective physiological endpoints (salivary cortisol) — is present in a minority of published studies. Flint et al. (2025; PMCID: PMC12339541) used salivary cortisol as an objective endpoint in a 4-arm blinded crossover trial. The mixed CBD, L-tryptophan, and alpha-casozepine treat attenuated cortisol, while CBD alone at two dose levels did not.

Ingredient-class evidence review

What clinical trial methodology reveals

The most informative trials share a common design pattern: blinded assessors, objective physiological endpoints, crossover or controlled designs, and explicit pre-registration of outcome measures. These methodological features reduce expectation bias and produce more interpretable results.

The fish-hydrolysate RCT (PMCID: PMC8464231) was double-blind and placebo-controlled — a higher standard than most supplement studies — and still documented substantial placebo-group improvements that complicated interpretation. This is not an isolated finding; it reflects the well-documented difficulty of measuring dog behavioral states through owner perception.

High inter-individual pharmacokinetic variability in CBD bioavailability — documented by both Di Salvo et al. (2023; PMCID: PMC10347378) and Flint et al. (2025; PMCID: PMC12339541) — introduces substantial within-group variance that small sample sizes cannot adequately power against. This variability may be a fundamental barrier to detecting true effects with the sample sizes typically used in canine supplement trials.

Evidence gaps and limitations

Controlled evidence for canine calming supplements is constrained by small sample sizes (the largest identified blinded trial enrolled 54 dogs across four arms), heterogeneous outcome measures across studies, and the frequent use of multi-ingredient formulations that prevent constituent-level attribution. Most published trials evaluate proprietary formulations of specific companies, which limits generalizability to other products even when they contain similar ingredient classes. For a deeper examination of specific ingredients and their evidence tiers, see the calming chew ingredients guide and the calming products guide.

Long-term efficacy data — whether effects persist over weeks or months of supplementation — is largely absent. Most controlled trials run 30-65 days, with no follow-up after the supplementation period ends.

The relationship between anxiety severity, phenotype, and ingredient efficacy is unexamined. All published trials pool dogs across anxiety phenotypes without stratifying by separation-related distress, noise phobia, or generalized anxiety — yet the pharmacological rationale for specific ingredients differs across anxiety types.

Frequently asked questions